Schering Ag Articles
Novartis shows off strong R&D pipeline at annual conference
31 January 2005
German pharma fails to move govt on prices
31 January 2005
New product launches in 2004
31 January 2005
Fougera debuts to new ophthalmics
24 January 2005
FDA issues approvable letter for Epix' MS-325
24 January 2005
Stock Commentary - European
17 January 2005
German drug co's to get 2005 sales boost?
10 January 2005
MorphoSys extends deal with Schering AG
10 January 2005
FDA approvable letter for Schering AG's Yaz
22 November 2004
Stock Commentary - Europe
22 November 2004
Schering AG looks to further job cuts
22 November 2004
Stock Commentary - Europe
15 November 2004
ILEX' loss grows for third quarter
1 November 2004
Stock Commentary - Europe
1 November 2004
Schering AG's three-qtr EPS rises 12%
25 October 2004
Stock Commentary - Europe
25 October 2004
Is biotech approaching a golden era? Firms showcase technologies at BioPartnering Euro
25 October 2004
Schering AG's Primovist completes EU's MRP
11 October 2004
FDA extends review period for MS-325
11 October 2004
Stock Commentary - Europe
4 October 2004
UPDATE: Ireland's Warner Chillcott mulls L1.7 billion offer from private equity group
27 September 2004
Genstruct and Berlex to study mechanisms of breast cancer
27 September 2004
Stock Commentary - Europe
20 September 2004
Schering AG's Angeliq on track in USA
20 September 2004
Schering AG dermatology business to be called Intendis
20 September 2004
Additional patent for Schering AG's Yasmin
20 September 2004
Schering AG's Bonefos granted priority review status by FDA
13 September 2004
Schering AG's Angeliq launched in Europe
6 September 2004
Letter from the Editor
6 September 2004
Jena therapeutics ops sold to Dermanpharm
23 August 2004
Stock Commentary - Europe
16 August 2004
EPIX/Schering AG's EP-2104R enters clinic
16 August 2004
Schering AG raises 2004 forecast on 2nd-qtr
2 August 2004
Chiron's 2nd-qtr income dips but sales rise
2 August 2004
AstraZeneca's 2nd-qtr sales jump 19%
2 August 2004
Schering-AG's low-dose Yasmin delayed
26 July 2004
Berlex to invest $60M into biopharm center
26 July 2004
EU green light for Schering AG's Nebido
19 July 2004
Stock Commentary - Europe
19 July 2004
Titan/Schering AG's Spheramine on track
19 July 2004
EPIX/Schering AG's MS-325 starts new trial
19 July 2004
NexMed and Schering AG sign deal for Alprox-TD
12 July 2004
Stock Commentary - Europe
12 July 2004
Stock Commentary - Europe
5 July 2004
Berlex acquires 16-acre site for manufacturing
5 July 2004
Stock Commentary - Europe
28 June 2004
Letter from the Editor
21 June 2004
Schering AG submits MS-325 MAA in EU
21 June 2004
Stock Commentary - Europe
14 June 2004
Schering AG's Menostar approved in the USA
14 June 2004
Schering to increase convenience of Betaferon use
14 June 2004
Stock Commentary - Europe
24 May 2004
Stock Commentary - Europe
10 May 2004
Barr's 3rd-qtr revenues rocket 87%
10 May 2004
Praecis and Schering AG sign Plenaxis accord
3 May 2004
Schering AG's 1st-qtr beats expectations
3 May 2004
Stock Commentary - Europe
26 April 2004
Schering AG criticized over board pay plan
12 April 2004
Schering AG and Barr in oxybutynin deal
12 April 2004
Sweden OKs Schering AG's Primovist
12 April 2004
German pharma on the defensive
5 April 2004
Schering AG well on path to future growth
15 March 2004
Positive new data for Schering AG's fasudil
15 March 2004
Genzyme to buy ILEX for $1 billion
8 March 2004
Stock Commentary - Europe
1 March 2004
Schering AG postpones analysts' conf
1 March 2004
MS-325 filing accepted by FDA
23 February 2004
Stock Commentary - Europe
16 February 2004
Schering AG's Climara Pro launched in USA
16 February 2004
UPDATE: Schering AG reports 6% "organic" sales growth for 2003, but conservative outlook
16 February 2004
Schering AG reports 6% "organic" sales growth for 2003
9 February 2004
Stock Commentary - Europe
9 February 2004
Schering AG halts Ad5FGF-4 trials
9 February 2004
German govt intervenes in Sanofi/Aventis fight
2 February 2004
Schering AG and Organon to test "male pill"
26 January 2004
Schering AG's Zevalin cleared by EC
26 January 2004
Stock Commentary - Europe
26 January 2004
MS-325 on track for US approval
22 December 2003
Schering AG files NDA for low-dose Yasmin
22 December 2003
Schering AG denies Reuters comments
22 December 2003
Schering AG's Finacea cleared in EU
22 December 2003
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
